S

    Sana Biotechnology Inc (SANA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.87
    -0.06 (-1.53%)

    Market Cap: $1.18B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(12/23)
    Avg Surprise
    -27.15%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.12-20.0%
    60d ago$-0.12-23.3%
    30d ago$-0.12-21.6%
    7d ago$-0.12-21.6%
    Current$-0.10
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.34 - $-0.11
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.22---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.13$-0.15+13.33%Beat+18.8%
    Mar 26
    		$-0.14$-0.15+6.67%Beat+30.0%
    Dec 25
    		$-0.16$-0.14-10.80%Miss+30.4%
    Sep 25
    		$-0.15$-0.19+21.05%Beat+44.4%
    Jun 25
    		$-0.16$-0.21+23.81%Beat+50.0%
    Mar 25
    		$-0.20$-0.20+0.00%Beat+37.5%
    Dec 24
    		$-0.23$-0.24+5.27%Beat+43.9%
    Sep 24
    		$-0.27$-0.27+0.00%Beat+34.1%
    Jun 24
    		$-0.32$-0.24-33.33%Miss+45.8%
    Mar 24
    		$-0.32$-0.22-45.45%Miss+25.6%
    Dec 23
    		$-0.41$-0.38-7.89%Miss-7.9%
    Sep 23
    		$-0.41$-0.45+8.89%Beat+14.6%
    Jun 23
    		$-0.59$-0.43-37.21%Miss-25.5%
    Mar 23
    		$-0.43$-0.37-16.22%Miss+8.5%
    Dec 22
    		$-0.38$-0.51+25.49%Beat+36.7%
    Sep 22
    		$-0.48$-0.39-23.08%Miss-29.7%
    Jun 22
    		$-0.47$-0.46-2.17%Miss-46.9%
    Mar 22
    		$-0.47$-0.38-23.68%Miss-62.1%
    Dec 21
    		$-0.60$-0.56-7.14%Miss+79.9%
    Sep 21
    		$-0.37$-0.50+26.00%Beat+92.5%
    Jun 21
    		$-0.32$-0.45+28.89%Beat-
    Mar 21
    		$-0.29$-0.58+50.00%Beat-
    Dec 20
    		$-2.98$-0.41-626.83%Miss-
    Sep 19
    		$-4.92$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.67EV/EBITDA-1.08x
    Price/FCF-8.47xFCF Yield-11.80%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-152.90%ROIC-69.95%
    Financial Health
    Debt/Equity0.59xInterest CoverageN/A
    Current Ratio1.38xQuick Ratio1.38x
    Trading Statistics
    Beta2.10Avg Volume2.51M
    52-Week High$6.5552-Week Low$2.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.93
    SMA 20$3.76
    SMA 50$3.57
    SMA 200$3.70
    EMA 10$3.91
    EMA 20$3.78
    EMA 50$3.58
    EMA 200$3.53

    MACD

    Line: 0.16Signal: 0.14Hist: 0.01

    ADX

    ADX: 25.0+DI: 26.1-DI: 19.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$3.61

    Bollinger Bands

    Upper Band$4.23
    Lower Band$3.29
    %B Position2483%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    54.3

    Momentum Oscillators

    Stoch %K70.4
    Stoch %D81.6
    Williams %R-40.6
    ROC (10d)5.2%
    Momentum0.19
    CCI (20d)32.8
    MFI (14d)55.3

    Volatility Measures

    ATR (14d)$0.23(6.1%)
    StdDev (20d)0.23
    Hist Vol80.4%(High)

    Volume Flow

    VWAP$3.84
    OBV-28.8M
    AD Line-103.3M
    CMF (20d)0.240

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.9x
    VWMA (20d)$3.79

    Pivot Points

    R3$4.29
    R2$4.20
    R1$4.07
    Pivot Point$3.98
    S1$3.84
    S2$3.75
    S3$3.62

    Advanced Oscillators

    TSI16.56
    Ultimate Osc53.7
    KST141.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$15.28M$0$0$0$0$0
    Cost of Revenue$0$0$3.05M$0$0$0$7.64M$0$0$0$7.54M$0
    Gross Profit$0$0$-3,053,000$0$0$0$7.64M$0$0$0$-7,541,000$0
    Operating Expenses$65.42M$48.61M$61.20M$43.52M$94.97M$50.63M$50.87M$61.76M$49.37M$110.72M$90.62M$2.18M
    R&D$54.64M$37.15M$49.01M$33.23M$40.02M$39.15M$31.70M$47.71M$32.93M$94.45M$62.82M$-17,002,000
    SG&A$10.78M$11.46M$12.19M$10.29M$10.34M$11.48M$17.28M$14.05M$16.44M$16.27M$20.78M$19.18M
    Operating Income$-65,420,000$-48,614,000$-61,199,000$-43,515,000$-94,975,000$-50,630,000$-50,866,000$-61,761,000$-49,372,000$-110,724,000$-90,619,000$-2,181,000
    Interest Income$1.13M$951,000$1.28M$1.00M$577,000$992,000$1.66M$2.58M$3.20M$3.03M$2.73M$2.86M
    Interest Expense$0$0$0$0$0$0$0$0$919,000$0$0$0
    Income Before Tax$-63,635,000$-47,210,000$-61,130,000$-42,152,000$-93,800,000$-49,389,000$-48,854,000$-59,924,000$-50,291,000$-107,690,000$-88,164,000$984,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-63,635,000$-47,210,000$-58,825,000$-42,152,000$-93,800,000$-49,389,000$-49,069,000$-59,924,000$-50,291,000$-107,475,000$-88,117,000$984,000
    EBITDA$-62,530,000$-45,770,000$-58,146,000$-39,964,000$-91,520,000$-46,732,000$-47,064,000$-58,446,000$-49,598,000$-106,978,000$-86,369,000$2.62M
    EBIT$-64,764,000$-48,161,000$-61,199,000$-43,155,000$-94,377,000$-50,381,000$-50,866,000$-62,503,000$-53,493,000$-110,724,000$-90,619,000$-1,878,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SANA

    News

    Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?

    Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost control and financial efficiency. While these results strengthen the investment case by easing near-term cash burn worries, the company still faces challenges including a short cash runway and skepticism regarding its share price valuation. Investors are encouraged to consider multiple perspectives and risks, including the need for clinical progress in its cell and gene engineering programs.

    Webull•8/22/26•
    Neutral

    Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?

    Sana Biotechnology (SANA) reported a narrower net loss and reduced loss per share for Q2 2026, indicating improved cost discipline. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress in its core programs. Investor opinions on the company's valuation vary widely, highlighting a need for careful consideration given the short cash runway and ongoing losses.

    Sahm•8/21/26•
    Somewhat-Bullish

    Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

    This article examines Sana Biotechnology's financial health, specifically its cash reserves and burn rate, to assess its ability to fund operations. It highlights that the company has sufficient cash for over two years at its current burn rate but warns that investors should closely monitor its future cash usage and potential capital raises. The analysis suggests that while the current cash position is strong, the burn rate is high, necessitating careful management.

    Moomoo•8/21/26•
    Neutral

    Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

    Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average "Moderate Buy" rating from nine analysts, with seven buy ratings, one hold, and one sell. The average 12-month price target for the stock is $9.33, significantly higher than its recent price of $3.74. Institutional investors hold a substantial 88.23% of Sana's shares, and the company recently reported a quarterly loss of $0.13 per share, beating analyst estimates.

    MarketBeat•8/21/26•
    Bullish

    Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative?

    Sana Biotechnology reported a narrower net loss and reduced loss per share for Q2 2026 and the first half of the year, signaling improved cost controls and financial efficiency. While this strengthens the investment case by easing concerns about cash burn, the fundamental drivers remain clinical progress and partnerships. Investors should still consider the short cash runway and "going concern" doubts.

    Simply Wall Street•8/20/26•
    Neutral

    Frequently Asked Questions About SANA

    Does SANA pay dividends?
    Sana Biotechnology Inc (SANA) does not currently pay a regular dividend.
    What is SANA's market cap?
    Sana Biotechnology Inc (SANA) has a market capitalization of $1.18B with a current stock price of $3.87.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In